Generate Biomedicines, Inc. (GENB)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch GENB
See up to 3 months of GENB. The 7-day demo opens the 1M and 3M ranges and puts GENB on your watchlist.
Start 7-day demoLatest GENB insider trades
About Generate Biomedicines, Inc. (GENB)
Generate Biomedicines, Inc. is an SEC registrant, filing under CIK 0002100782, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site. Its offering priced on 27 February 2026 and it trades on NASDAQ.
GENB Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 1,000 | $16K |
GENB insider transactions (Form 4)
4616 Form 4 filings on record, the earliest from Mar 2, 2026, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Frances Arnold - Director | Open-market sale | Common Stock | 1,000 | $16.00 footnote F2 | $16K | |
| ||||||
| Michael Nally - Officer | Open-market purchase | Common Stock | 20,000 | $12.00 | $240K | |
| Rupert Vessey | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
| Beth Grous - Officer | Open-market purchase | Common Stock | 300 | $16.00 | $5K | |
| Beth Grous - Officer | Grant or award | Stock Option (Right to Buy) | 114,020 | $0.00 | - | |
| Frances Arnold | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
| Laurie Anne Lee - Officer | Grant or award | Stock Option (Right to Buy) | 42,230 | $0.00 | - | |
| Sean Martin - Officer | Grant or award | Stock Option (Right to Buy) | 190,034 | $0.00 | - | |
| Nancy A. Simonian | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
| Jason Silvers - Officer | Open-market purchase | Common Stock | 500 | $16.00 | $8K | |
| Jason Silvers - Officer | Open-market purchase | Common Stock | 500 | $16.00 | $8K | |
| Jason Silvers - Officer | Open-market purchase | Common Stock | 1,000 | $16.00 | $16K | |
| Jason Silvers - Officer | Grant or award | Stock Option (Right to Buy) | 295,608 | $0.00 | - | |
| Jason Silvers - Officer | Grant or award | Stock Option (Right to Buy) | 274,493 | $0.00 | - | |
 Noubar Afeyan | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
| Noubar Afeyan | Other | Series A Preferred Stock | 18,483,785 | $0.00 | - | |
| Noubar Afeyan | Other | Common Stock | 12,723,940 | - footnote F1 | - | |
| Noubar Afeyan | Other | Common Stock | 13,702,224 | - footnote F1 | - | |
| Noubar Afeyan | Other | Common Stock | 987,491 | - footnote F1 | - | |
| Noubar Afeyan | Other | Common Stock | 2,777,752 | - footnote F1 | - | |
| Noubar Afeyan | Other | Common Stock | 2,777,752 | - footnote F1 | - | |
| Noubar Afeyan | Open-market purchase | Common Stock | 1,562,500 | $16.00 | $25.00M | |
| Noubar Afeyan | Open-market purchase | Common Stock | 1,562,500 | $16.00 | $25.00M | |
| Noubar Afeyan | Open-market purchase | Common Stock | 1,562,500 | $16.00 | $25.00M | |
| Noubar Afeyan | Other | Series A Preferred Stock | 17,016,215 | $0.00 | - | |
| Noubar Afeyan | Other | Series A Preferred Stock | 1,500,000 | $0.00 | - | |
| Noubar Afeyan | Other | Series B Preferred Stock | 843,881 | $0.00 | - | |
| Noubar Afeyan | Other | Series B Preferred Stock | 1,265,822 | $0.00 | - | |
| Noubar Afeyan | Other | Series B Preferred Stock | 2,953,586 | $0.00 | - | |
| Noubar Afeyan | Other | Series B Preferred Stock | 2,109,704 | $0.00 | - | |
| Noubar Afeyan | Other | Series C Preferred Stock | 2,531,644 | $0.00 | - | |
| Noubar Afeyan | Other | Series C Preferred Stock | 1,265,822 | $0.00 | - | |
| Noubar Afeyan | Other | Series C Preferred Stock | 2,109,704 | $0.00 | - | |
| ||||||
| Gevorg Grigoryan - Officer | Grant or award | Stock Option (Right to Buy) | 295,608 | $0.00 | - | |
| Gevorg Grigoryan - Officer | Grant or award | Stock Option (Right to Buy) | 196,368 | $0.00 | - | |
| Michael Nally - Officer | Other | Common Stock | 658,327 | - footnote F1 | - | |
| Michael Nally - Officer | Grant or award | Stock Option (Right to Buy) | 844,595 | $0.00 | - | |
| Michael Nally - Officer | Grant or award | Stock Option (Right to Buy) | 844,595 | $0.00 | - | |
| Michael Nally - Officer | Other | Series A Preferred Stock | 1,000,000 | $0.00 | - | |
| ||||||
 Stephane Bancel | Other | Common Stock | 724,160 | - footnote F1 | - | |
| Stephane Bancel | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
| Stephane Bancel | Other | Series A Preferred Stock | 1,100,000 | $0.00 | - | |
| ||||||
| Jane L. Mendillo | Open-market purchase | Common Stock | 1,500 | $16.00 | $24K | |
| Jane L. Mendillo | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
 Marsha Fanucci | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
| Paul Gray Parker | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
Item 7.01, 9.01
Item 2.02, 9.01
Item 2.02, 9.01
Recent GENB Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Frances Arnold | Director | 11,409 | $185K | View on EDGAR | |
| Frances Arnold | Director | 32,210 |
GENB insider trading FAQ
What is the latest insider trade for GENB?
Generate Biomedicines, Inc. (GENB) had 1 insider filing in the last 90 days, with the most recent on 3 September 2026. The full record for GENB runs to 16 Form 4 filings, the earliest from 2 March 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying GENB stock?
No insider purchases of GENB were filed in the last 90 days. 9 purchases are on record for this company.
How many insiders are selling GENB stock?
1 insider sale of GENB was filed in the last 90 days, totaling $16K.
Where can I see GENB SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects GENB Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Frances Arnold view on EDGAR
- - Michael Nally view on EDGAR
- - Rupert Vessey view on EDGAR
- - Beth Grous view on EDGAR
- - Frances Arnold view on EDGAR
- - Laurie Anne Lee view on EDGAR
- - Sean Martin view on EDGAR
- - Nancy A. Simonian view on EDGAR
- - Jason Silvers view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where GENB's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow GENB with a 7-day demo
- GENB on your watchlist
- Every GENB Form 4 filing on record
- Up to 3 months of GENB price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
